Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Anastasia Tsagianni, MD, Konstantinos Lontos, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic J. Farah, MD, Robert L. Redner, MD, Annie Im, MD, Kathleen A. Dorritie, MD, Alison R. Sehgal, MD, James M. Rossetti, DO, Melissa Saul, MS, William Gooding, MS, Michael Boyiadzis, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138561

Published: 2020

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Rachel J. Cook, MD, Tamara Moyo, MD PhD, Jane L. Liesveld, MD, David A. Rizzieri, MD, Eytan M. Stein, MD, Stephane De Botton, MD PhD, Gail J. Roboz, MD, Mikkael A. Sekeres, MD MS, Joseph G. Jurcic, MD, Azra Raza, MD, Robert L. Redner, MD, Dale L. Bixby, MD PhD, Jorge E. Cortes, MD, Kristin Stephens, Angela Volkert, Qing Kang, PhD, Emmanuelle Di Tomaso, PhD, David A. Roth, MD, Carlos E Vigil, MD

Blood (2018) 132 (Supplement 1): 2735.

https://doi.org/10.1182/blood-2018-99-111285

Published: 2018

Journal Articles

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Asha Ricciuti, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, James M. Rossetti, DO, Yongli Shuai, PhD, Daniel Normolle, PhD, Rahim Remtulla, MD, Shawn Tahata, MD, Michael Boyiadzis, MD, Annie Im, MD

Blood (2018) 132 (Supplement 1): 4000.

https://doi.org/10.1182/blood-2018-99-113935

Published: 2018

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

Blood (2017) 130 (Supplement 1): 2633.

https://doi.org/10.1182/blood.V130.Suppl_1.2633.2633

Published: 2017

Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD

Blood (2016) 128 (22): 1649.

https://doi.org/10.1182/blood.V128.22.1649.1649

Published: 2016

Journal Articles

Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials

Suzanne Lentzsch, Nicolas Villanueva, MD, James Nguyen, BS, Heather Landau, MD, Nikoletta Lendvai, MDPhD, Susanna Miao, BA, Jordan M. Schecter, MD, Mariamne Reyna, BS, Markus Y Mapara, MD PhD, Robert L. Redner, MD, David J Chung, MDPhD, Alexander M. Lesokhin, MD, Tarun Kewalramani, MD, Sergio Giralt, MD, Raymond L. Comenzo, MD, Ola Landgren, MD PhD, Hani Hassoun, MD

Blood (2015) 126 (23): 1975.

https://doi.org/10.1182/blood.V126.23.1975.1975

Published: 2015

Journal Articles

Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Annie Im, MD, Jing-Zhou Hou, MD PhD, Anastasios Raptis, MD, Mounzer Agha, MD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, Ann Welsh, RN, Daniel E. Johnson, PhD, Daniel Normolle, PhD, Michael Boyiadzis, MD

Blood (2014) 124 (21): 2265.

https://doi.org/10.1182/blood.V124.21.2265.2265

Published: 2014

Journal Articles

NPM-RAR Binding To Tradd Selectively Blocks TNF-Induced Apoptosis While Allowing TNF Activation Of JNK

Robert L. Redner, MD, Anuja Chattopadhyay, Brian L. Hood, PhD, Thomas P. Conrads, PhD

Blood (2013) 122 (21): 4904.

https://doi.org/10.1182/blood.V122.21.4904.4904

Published: 2013

Journal Articles

Outcomes of Hematopoietic Cell Transplantation in Patients with Refractory Acute Myeloid Leukemia

Annie Im, MD, Navkiranjit Gill, DO, Diana Cunningham, MS, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD, PhD, Robert L. Redner, MD, Julie Phillips, MSN, CRNP, BC, Michael Boyiadzis, MD, MHSc

Blood (2012) 120 (21): 4531.

https://doi.org/10.1182/blood.V120.21.4531.4531

Published: 2012

Journal Articles

NPM-RAR Binds to Tradd and Impedes the Extrinsic Apoptotic Pathway

Robert L. Redner, MD, Anuja Chattopadhyay, Brian L. Hood, PhD, Thomas P. Conrads, PhD

Blood (2012) 120 (21): 5126.

https://doi.org/10.1182/blood.V120.21.5126.5126

Published: 2012

Journal Articles

NPM-RAR Enhances NFκB Transcriptional Activity

Robert L. Redner, MD, Irina Abecassis, PhD, Elizabeth A. Rush, Anuja Chattopadhyay

Blood (2012) 120 (21): 5117.

https://doi.org/10.1182/blood.V120.21.5117.5117

Published: 2012

Journal Articles

Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of Phase I/II Open-Label, Dose Escalation Study

Blood (2011) 118 (21): 304.

https://doi.org/10.1182/blood.V118.21.304.304

Published: 2011

Journal Articles

A Randomized Clinical Trial of Lenalidomide and Dexamethasone with and without Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Interim Study Results,

Blood (2011) 118 (21): 4142.

https://doi.org/10.1182/blood.V118.21.4142.4142

Published: 2011

Journal Articles

Combination of Bendamustine, Lenalidomide, and Dexamethasone In Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of a Phase I Clinical Trial

Suzanne Lentzsch, MD, PhD, Amy O'Sullivan, RN, BSN, Ryan Kennedy, BS, Navkiranjit Gill, DO, Carrie Andreas, PA-C, Diane Gardner, MSN, CRNP, BC, Silvana Lalo, MBA, Steve Burt, NP, Robert L. Redner, MD, Robert Volkin, MD, David Roodman, MD, PhD, Markus Y Mapara, MD, PhD, Frank Viverette, MD, Mounzer Agha, MD, Jeffrey A. Zonder, MD

Blood (2010) 116 (21): 989.

https://doi.org/10.1182/blood.V116.21.989.989

Published: 2010

Journal Articles

Effectiveness of Peripheral Blood (PB) Molecular Monitoring by Quantitative RT-PCR (Q-PCR) in Phase II Acute Promyelocytic Leukemia (APL) Trial J0422.

Robert E Gallagher, MD, Esther L Schachter- Tokarz, BA, Lawrence E. Morris, Tianna Dauses, BSN, Ivana Gojo, MD, Marcel P. Devetten, MD, Katarzyna Jamieson, MD, Robert L. Redner, MD, Mikkael A. Sekeres, MD, MS, Ibitayo Owoeye, MD, Steven D. Gore, MD

Blood (2008) 112 (11): 1502.

https://doi.org/10.1182/blood.V112.11.1502.1502

Published: 2008

Journal Articles

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Steven D. Gore, MD, Lawrence Morris, MD, Ivana Gojo, MD, Marcel P. Devetten, MD, Katarzyna Jamieson, MD, Mikkael A. Sekeres, MD, MS, Robert J. Arceci, MD, PhD, Robert L. Redner, MD, Tianna Dauses, BSN, Esther L Schachter-Tokarz, Ibitayo Owoeye, MD, Robert E. Gallagher, MD

Blood (2008) 112 (11): 1932.

https://doi.org/10.1182/blood.V112.11.1932.1932

Published: 2008

Journal Articles

Efficacy of Mitoxantrone and Etoposide in Patients with Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy.

Rajesh Sehgal, MD, Wassim McHayleh, MD, James Natale, Anastasios Raptis, MD, Mounzer Agha, MD, Robert L. Redner, MD, Gene Richard, Ann Welsh, Kenneth A. Foon, MD, Michael Boyiadzis, MD

Blood (2007) 110 (11): 4385.

https://doi.org/10.1182/blood.V110.11.4385.4385

Published: 2007

Journal Articles

Dominant-Negative Effect of NPM-RAR on NPM Mediated Regulation of p53.

Robert L. Redner, MD, Erin M. Swaney, Elizabeth A. Rush

Blood (2006) 108 (11): 1456.

https://doi.org/10.1182/blood.V108.11.1456.1456

Published: 2006

Journal Articles

Fusion of NPM to RARA in t(5;17) Disrupts Its Ability To Interact with YY1 Transcription Factor.

Robert L. Redner, MD, Sumandeep Sumandeep, MS

Blood (2004) 104 (11): 4313.

https://doi.org/10.1182/blood.V104.11.4313.4313

Published: 2004

Journal Articles

A Novel t(3;17) Variant of Acute Promyelocytic Leukemia with Rearrangement of the RARA Locus.

Robert L. Redner, MD, Lydia C. Contis, MD, Carol Evans, MD, Maureen E. Sherer, MS, Sofia Shekhter-Levin, MD, PhD

Blood (2004) 104 (11): 4428.

https://doi.org/10.1182/blood.V104.11.4428.4428

Published: 2004

NARROW

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials

Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

NPM-RAR Binding To Tradd Selectively Blocks TNF-Induced Apoptosis While Allowing TNF Activation Of JNK

Outcomes of Hematopoietic Cell Transplantation in Patients with Refractory Acute Myeloid Leukemia

NPM-RAR Binds to Tradd and Impedes the Extrinsic Apoptotic Pathway

NPM-RAR Enhances NFκB Transcriptional Activity

Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of Phase I/II Open-Label, Dose Escalation Study

A Randomized Clinical Trial of Lenalidomide and Dexamethasone with and without Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Interim Study Results,

Combination of Bendamustine, Lenalidomide, and Dexamethasone In Patients with Refractory or Relapsed Multiple Myeloma Is Safe and Highly Effective: Results of a Phase I Clinical Trial

Effectiveness of Peripheral Blood (PB) Molecular Monitoring by Quantitative RT-PCR (Q-PCR) in Phase II Acute Promyelocytic Leukemia (APL) Trial J0422.

Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy.

Efficacy of Mitoxantrone and Etoposide in Patients with Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy.

Dominant-Negative Effect of NPM-RAR on NPM Mediated Regulation of p53.

Fusion of NPM to RARA in t(5;17) Disrupts Its Ability To Interact with YY1 Transcription Factor.

A Novel t(3;17) Variant of Acute Promyelocytic Leukemia with Rearrangement of the RARA Locus.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only